Article: HemoBioTech Engages CRO to Facilitate Clinical Study in India of Its Human Blood Substitute, HemoTech.

'HemoBioTech is developing what we hope will be the world's first viable substitute for human blood, licensed on an exclusive basis from Texas Tech University Health Sciences Center.'

Lt. General Bernhard Mittemeyer, M.D. Interim President, Texas Tech University Health Sciences Center; Former U.S. Army Surgeon General; HemoBioTech Director

DALLAS, June 21 /PRNewswire-FirstCall/ -- HemoBioTech (BULLETIN BOARD: HMBT) announced today that it has engaged Paragon Biomedical (http://www.parabio.com/) to provide regulatory and clinical services in India related to the Company's proposed human blood substitute, HemoTech. Paragon will submit preclinical data ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!